News

Koninklijke Philips PHG reported fourth-quarter 2025 earnings of €0.41 per share. The company reported a loss of €0.35 per share in the year-ago quarter.

The company’s sales increased 1.1% on a year-over-year basis to €5.09 billion. Comparable sales increased 7% year over year, which was driven by growth across all segments. The Diagnosis & Treatment segment recorded 4% growth, Connected Care recorded 7% growth, and Personal Health showed 14% growth.

Further, Philips’ comparable order intake increased 7% year over year in the fourth quarter.

Sales increased 7% year over year on a comparable basis in growth geographies. Growth geographies showed 15% growth, mainly driven by Personal Health. Comparable sales in Mature geographies grew 4% in the reported quarter, mainly driven by North America and with strong contribution from Connected Care.

Koninklijke Philips N.V. Price, Consensus and EPS Surprise

Philips’ stock lost 3.46% in pre-market trading.

PHG’s Segmental Update

Diagnosis & Treatment revenues declined 2% from the year-ago quarter to €2.40 billion. Comparable sales increased 4% year over year. Image Guided Therapy showed double-digit growth, while Precision Diagnosis was flat.

Connected Care revenues were in line year over year at €1.42 billion. Comparable sales increased 7% year over year, mainly due to double-digit growth in Monitoring and mid-single-digit growth in Enterprise Informatics.

Personal Health revenues grew 9% year over year to €1.11 billion. Comparable sales increased 14% year over year, driven by double-digit growth in Growth geographies and mid-single-digit growth in Mature geographies.

Other segment sales amounted to €155 million, up 2.6% on a year-over-year basis.

PHG’s Operating Details

Gross margin contracted 600 basis points (bps) on a year-over-year basis to 44.9% in the reported quarter.

General & administrative expenses, as a percentage of sales, were 15.3%, which expanded 40 bps on a year-over-year basis. Moreover, selling expenses decreased 100 bps year over year to 22.5%. Research & development expenses decreased 100 bps to 8.4%.

Restructuring, acquisition-related, and other items amounted to a loss of €179 million compared with €286 million a year ago.

Philips remains on track to deliver its three-year €2.5 billion productivity program, including €0.8 billion in savings in 2025.

Phillips adjusted EBITA — the company’s preferred measure of operational performance — increased 13.4% year over year to €770 million. EBITA margin expanded 160 bps on a year-over-year basis to 15.1% in the reported quarter.

Diagnosis & Treatment’s adjusted EBITA margin contracted 30 bps on a year-over-year basis to 11.8%.

Connected Care’s adjusted EBITA margin was 16.5% in the reported quarter, which expanded 150 bps year over year.

Personal Health’s adjusted EBITA margin contracted 500 bps on a year-over-year basis to 23%.

PHG’s Balance Sheet

As of Dec. 31, 2025, Philips’ cash and cash equivalents were €2.40 billion compared with €1.91 billion as of Sept. 30, 2025.

Total debt was €8.084 billion compared with €8.385 billion as of Sept. 30, 2025.

Operating cash flow was €1.39 billion compared with the year-ago quarter’s €1.45 billion.

In the quarter under review, free cash flow was €1.2 billion compared with the year-ago quarter’s €1.28 billion.

PHG Initiates 2026 Guidance

Philips expects to deliver 3%-4.5% of comparable sales growth.

Further, the adjusted EBITA margin is expected to be between 12.5% and 13%.

Free cash flow is expected to be between €1.3 billion and €1.5 billion in 2026.

PHG’s Zacks Rank & Stocks to Consider

Philips currently has a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader Zacks Computer and Technology sector include Analog Devices ADI, Applied Materials AMAT, and MKS MKSI. While MKSI sports a Zacks Rank #1 (Strong Buy), Analog Devices and Applied Materials carry a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Analog Devices’ shares have gained 60.3% in the past 12-month period. Analog Devices is scheduled to release first-quarter fiscal 2026 results on Feb. 18, 2026.

Applied Materials shares have returned 79.8% in the past 12-month period. AMAT is scheduled to release its first-quarter fiscal 2026 results on Feb. 12, 2026.

MKS shares have gained 127.7% in the past 12-month period. MKS is set to report its fourth-quarter 2025 results on Feb. 17, 2026.

Zacks' Research Chief Picks Stock Most Likely to "At Least Double"

Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.

See Our Top Stock to Double (Plus 4 Runners Up) >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.